The Neisseria gonorrhoeae Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Neisseria gonorrhoeae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neisseria gonorrhoeae Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neisseria gonorrhoeae Infections and features dormant and discontinued products.
GlobalData tracks 34 drugs in development for Neisseria gonorrhoeae Infections by 26 companies/universities/institutes. The top development phase for Neisseria gonorrhoeae Infections is preclinical with 20 drugs in that stage. The Neisseria gonorrhoeae Infections pipeline has 33 drugs in development by companies and one by universities/ institutes. Some of the companies in the Neisseria gonorrhoeae Infections pipeline products market are: Microbiotix, TherapyX and Evaxion Biotech.
The key targets in the Neisseria gonorrhoeae Infections pipeline products market include DNA Topoisomerase IV, DNA Topoisomerase II, and DNA Gyrase.
The key mechanisms of action in the Neisseria gonorrhoeae Infections pipeline product include DNA Topoisomerase IV Inhibitor with three drugs in Phase III. The Neisseria gonorrhoeae Infections pipeline products include ten routes of administration with the top ROA being Oral and seven key molecule types in the Neisseria gonorrhoeae Infections pipeline products market including Small Molecule, and Vaccine.
Neisseria gonorrhoeae Infections overview
Neisseria gonorrhoeae, the bacterium accountable for the sexually transmitted infection (STI) gonorrhea, is a notable public health issue causing substantial global morbidity in both resource-rich and resource-poor nations. The diagnosis and treatment of this infection entail considerable financial expenditures each year. Similar to other sexually transmitted infections (STIs), gonorrhea has a disproportionate impact on young adults. The obligate human pathogen N. gonorrhoeae predominantly presents as urethritis in men and cervicitis in women.
For a complete picture of Neisseria gonorrhoeae Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
